Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Cost of Revenue (2019 - 2025)

Harmony Biosciences Holdings' Cost of Revenue history spans 7 years, with the latest figure at -$10.3 million for Q4 2025.

  • For Q4 2025, Cost of Revenue fell 220.86% year-over-year to -$10.3 million; the TTM value through Dec 2025 reached $119.5 million, up 7.75%, while the annual FY2025 figure was $119.5 million, 7.75% up from the prior year.
  • Cost of Revenue for Q4 2025 was -$10.3 million at Harmony Biosciences Holdings, down from $59.6 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $59.6 million in Q3 2025 and bottomed at -$10.3 million in Q4 2025.
  • The 5-year median for Cost of Revenue is $25.7 million (2022), against an average of $25.0 million.
  • The largest annual shift saw Cost of Revenue skyrocketed 206.68% in 2021 before it plummeted 220.86% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $30.4 million in 2021, then decreased by 11.61% to $26.9 million in 2022, then rose by 0.0% to $26.9 million in 2023, then crashed by 68.35% to $8.5 million in 2024, then tumbled by 220.86% to -$10.3 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Cost of Revenue are -$10.3 million (Q4 2025), $59.6 million (Q3 2025), and $38.2 million (Q2 2025).